Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement



天津泰達生物醫學工程股份有限公司 Tianjin TEDA Biomedical Engineering Company Limited

(a joint stock company incorporated in the People's Republic of China with limited liability) (Stock code: 8189)

## **DELAY IN DESPATCH OF CIRCULAR**

Reference is made to the announcement of Tianjin TEDA Biomedical Engineering Company Limited (the "**Company**") dated 26 March 2021 in relation to, among other things, the entering into of the Agreements for variation of terms of a major transaction in relation to the acquisition of 51% shareholding interest in SJK (the "**Announcement**"). Capitalised terms used herein shall have the same meanings as those defined in the Announcement unless the context requires otherwise.

As disclosed in the Announcement, a circular containing, among other things, further details of the Agreements and the transactions contemplated thereunder (the "**Circular**") is expected to be despatched to the Shareholders on or before 21 April 2021.

As additional time is required for the Company to prepare and finalise the information to be included in the Circular, in particular the financial information of the Group, the despatch of the Circular will be delayed to a date falling on or before 31 May 2021.

> By order of the Board **Tianjin TEDA Biomedical Engineering Company Limited Sun Li** *Chairman*

Tianjin, the PRC 21 April 2021

As at the date of this announcement, the executive Directors are Sun Li, Hao Zhihui and He Xin; the non-executive Directors are Cao Aixin, Li Ximing and Gai Li; the independent non-executive Directors are Li Xudong, Wang Yongkang and Gao Chun.

This announcement, for which the directors are willing to collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief that the information contained in this announcement is accurate and complete in all material respects and is not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the "Latest Listed Company Information" page on the GEM website at www.hkgem.com for at least seven days from the date of its posting. This announcement will also be published and remain on the website of the Company at www.bioteda.com.